Olutasidenib
HCRN-AML24-687
Phase 2 small_molecule active
Quick answer
Olutasidenib for IDH1 Mutation is a Phase 2 program (small_molecule) at Atrium Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Atrium Therapeutics
- Indication
- IDH1 Mutation
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active